Recent preclinical and clinical studies have demonstrated that checkpoint blockade using anti‐CTLA‐4, anti‐PD‐1, and anti‐PD‐L1 antibodies can be successful for cancer immunotherapy 17, 18, 19. This evidence concerns the gene CTLA4 and cancer.